Acute Myeloid Leukemia Clinical Trials

157 studies are recruiting for acute myeloid leukemia in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

   This phase I trial tests the safety, side effects, and best dose of SM08502 (cirtuvivint) alone and in combination with ASTX727 in treating patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Cirtuvivint may stop the growth of cancer cells by blocking some of the enzymes…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Yale University, New Haven, Connecticut

   Locations

   23 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT06484062 on ClinicalTrials.gov

2. Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

   This phase II MyeloMATCH treatment trial tests whether the standard approach of cytarabine and daunorubicin in comparison to the following experimental regimens works to shrink cancer in patients with high risk acute myeloid leukemia (AML): 1) daunorubicin and cytarabine liposome alone; 2) cytarabi…

   Stage

   Phase 2

   Ages

   18 to 59

   Site

   University of Alabama at Birmingham Cancer Center, Birmingham, Alabama

   Locations

   227 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT05554406 on ClinicalTrials.gov

3. MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

   This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the course of their myeloid cancer (acute myeloid leukemia or myelodysplastic syndrom…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Alabama at Birmingham Cancer Center, Birmingham, Alabama

   Locations

   360 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT05564390 on ClinicalTrials.gov

4. Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT)

   This is a first in children prospective study of allogeneic hematopoietic cell transplant using a centrally manufactured engineered donor graft (Orca-Q). The study will assess safety and efficacy of Orca-Q in pediatric patients with hematologic malignancies.

   Stage

   Phase 1

   Ages

   Up to 50

   Site

   University of Florida, Gainesville, Florida

   Locations

   4 in total

   Run by

   University of Florida

   See if you can join NCT05322850 on ClinicalTrials.gov

5. 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome

   This phase I trial tests the safety, side effects, best dose, and effectiveness of 225Ac-DOTA-Anti-CD38 daratumumab monoclonal antibody in combination with fludarabine, melphalan and total marrow and lymphoid irradiation (TMLI) as conditioning treatment for donor stem cell transplant in patients wi…

   Stage

   Phase 1

   Ages

   18 to 70

   Site

   City of Hope Medical Center, Duarte, California

   Run by

   City of Hope Medical Center

   See if you can join NCT06287944 on ClinicalTrials.gov

6. Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

   This phase II MyeloMATCH treatment trial compares ASTX727 with standard duration versus shorter duration of venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML). ASTX727 is a combination of decitabine and cedazuridine. Decitabine is in a class of medications called hypomethy…

   Stage

   Phase 2

   Ages

   60 and older

   Site

   Kootenai Health - Coeur d'Alene, Coeur d'Alene, Idaho

   Locations

   52 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT07437950 on ClinicalTrials.gov

7. Study of REM-422 in Patients With AML or Higher Risk MDS

   The goal of this study is to determine the safety and antitumor effects of REM-422, a MYB mRNA degrader, in people with Higher Risk MDS and relapsed/refractory AML

   Stage

   Phase 1

   Ages

   18 and older

   Site

   City of Hope, Duarte, California

   Locations

   9 in total

   Run by

   Remix Therapeutics

   See if you can join NCT06297941 on ClinicalTrials.gov

8. Prophylactic DLI-X for Leukemia Relapse After HCT

   The primary objective of this proposal is to conduct the first-in-human randomized clinical trial evaluating prophylactic DLI-X (pro-DLI-X) for relapse prevention following matched sibling donor (MSD) or haploidentical (haplo) hematopoietic cell transplantation (HCT) in patients with hematologic ma…

   Stage

   Phase 1

   Ages

   Up to 65

   Site

   The University of Arizona Cancer Center, Tucson, Arizona

   Run by

   University of Arizona

   See if you can join NCT07254793 on ClinicalTrials.gov

9. A Home-Based Exercise Intervention (CAREFit-BMT) in Improving Heart Function Among Patients With High Risk Acute Myeloid Leukemia Undergoing Stem Cell Transplant

   This clinical trial studies how well a home-based exercise intervention called Cardiorespiratory Fitness in Bone Marrow Transplant Program (CAREFit-BMT) works in improving heart function among patients with high risk acute myeloid leukemia (AML) undergoing stem cell transplant. Older adults and tho…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington

   Run by

   University of Washington

   See if you can join NCT07616921 on ClinicalTrials.gov

10. FH-WT1-E50 TCR T Cells With Azacitidine for the Treatment of Minimal Residual Disease Positive Acute Myeloid Leukemia

    This phase I trial tests the safety, side effects and best dose of FH-WT1-E50 TCR T cells with azacitidine for the treatment of minimal residual disease (MRD) positive acute myeloid leukemia (AML). T cells are infection fighting blood cells that can kill tumor cells. The T cells given in this study…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington

    Run by

    Fred Hutchinson Cancer Center

    See if you can join NCT07645469 on ClinicalTrials.gov

11. Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

    This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in the laboratory may help researchers develop tests for the earl…

    Stage

    Not phased

    Ages

    40 to 75

    Site

    Anchorage Associates in Radiation Medicine, Anchorage, Alaska

    Locations

    747 in total

    Run by

    Alliance for Clinical Trials in Oncology

    See if you can join NCT05334069 on ClinicalTrials.gov

12. Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

    This phase II MyeloMATCH treatment trial compares cytarabine with daunorubicin versus cytarabine with daunorubicin and venetoclax versus venetoclax with azacitidine for the treatment of younger patients with intermediate risk acute myeloid leukemia (AML). Cytarabine is a drug that inhibits some of …

    Stage

    Phase 2

    Ages

    18 to 59

    Site

    University of Alabama at Birmingham Cancer Center, Birmingham, Alabama

    Locations

    187 in total

    Run by

    National Cancer Institute (NCI)

    See if you can join NCT05554393 on ClinicalTrials.gov

13. Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

    This phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib in treating older and unfit patients with acute myeloid leukemia and FLT3 mutations. Azacitidine is a drug that is absorbed in…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of Alabama at Birmingham Cancer Center, Birmingham, Alabama

    Locations

    229 in total

    Run by

    National Cancer Institute (NCI)

    See if you can join NCT06317649 on ClinicalTrials.gov

14. Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

    This phase I trial studies the safety of transplantation with a haploidentical donor peripheral blood stem cell graft depleted of TCRαβ+ cells and CD19+ cells in conjunction with the immunomodulating drug, Zoledronate, given in the post-transplant period to treat pediatric patients with relapsed or…

    Stage

    Phase 1

    Ages

    0 to 21

    Site

    University of Wisconsin Carbone Cancer Center, Madison, Wisconsin

    Run by

    University of Wisconsin, Madison

    See if you can join NCT02508038 on ClinicalTrials.gov

15. Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

    This phase II MyeloMATCH treatment trial studies how well ASTX727 and venetoclax plus enasidenib works compared to ASTX727 and venetoclax alone for the treatment of older patients with newly diagnosed acute myeloid leukemia (AML) or younger patients who are considered unfit for standard treatment, …

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Banner University Medical Center - Tucson, Tucson, Arizona

    Locations

    138 in total

    Run by

    National Cancer Institute (NCI)

    See if you can join NCT06672146 on ClinicalTrials.gov

16. Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent

    This phase II trial studies how well giving olutasidenib with azacitidine, followed by olutasidenib maintenance, works in treating patients with IDH1-mutated acute myeloid leukemia (AML) who have received prior treatment with venetoclax plus a hypomethylating agent (HMA-Ven). Olutasidenib and azaci…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    UCI Health Chao Family Comprehensive Cancer Center, Orange, California

    Locations

    2 in total

    Run by

    University of California, Davis

    See if you can join NCT07304011 on ClinicalTrials.gov

17. Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases

    This phase II trial studies how well giving an umbilical cord blood transplant together with cyclophosphamide, fludarabine, and total-body irradiation (TBI) works in treating patients with hematologic diseases. Giving chemotherapy, such as cyclophosphamide, fludarabine and thiotepa, and TBI before …

    Stage

    Phase 2

    Ages

    0 to 65

    Site

    Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington

    Run by

    Fred Hutchinson Cancer Center

    See if you can join NCT06013423 on ClinicalTrials.gov

18. Immune Profile of Acute Myeloid Leukemia Patients Receiving Azacitidine Plus Venetoclax Induction Chemotherapy

    This study investigates the immune profile of patients receiving treatment with venetoclax plus azacitidine for acute myeloid leukemia (AML). Studying the information gathered from the immune profile from blood and bone marrow samples may help researchers understand the associated responses to the …

    Stage

    Not phased

    Ages

    18 and older

    Site

    Mayo Clinic in Florida, Jacksonville, Florida

    Locations

    3 in total

    Run by

    Mayo Clinic

    See if you can join NCT06279572 on ClinicalTrials.gov

19. CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant

    This phase II clinical trial tests how well the cytomegalovirus-modified vaccinica Ankara (CMV-MVA) Triplex vaccine given to human leukocyte antigens (HLA) matched related stem cell donors works to prevent cytomegalovirus (CMV) infection in patients undergoing hematopoietic stem cell transplant. Th…

    Stage

    Phase 2

    Ages

    18 to 75

    Site

    City of Hope Medical Center, Duarte, California

    Locations

    3 in total

    Run by

    City of Hope Medical Center

    See if you can join NCT06059391 on ClinicalTrials.gov

20. A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)

    The primary purpose of Phase 1 is to characterize the safety and tolerability to identify the recommended dose (RD) of Debio 1562M for further development. The primary objective of Phase 2 is to evaluate the antileukemic activity of Debio 1562M.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    City of Hope Comprehensive Cancer Center, Duarte, California

    Locations

    7 in total

    Run by

    Debiopharm International SA

    See if you can join NCT06969430 on ClinicalTrials.gov

21. Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)

    This is a Phase I/II study evaluating safety and efficacy of proteasome inhibitor (bortezomib) in combination with CPX-351 (liposomal daunorubicin and cytarabine) for the treatment of newly-diagnosed TP53-mutated acute myeloid leukemia (TP53m AML). The primary endpoint of the study is to define saf…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Masonic Cancer Center, Minneapolis, Minnesota

    Run by

    Masonic Cancer Center, University of Minnesota

    See if you can join NCT07008638 on ClinicalTrials.gov

22. A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant

    This phase Ib trial tests the safety, side effects, and how well cytomegalovirus (CMV)-modified vaccinia Ankara (MVA) Triplex vaccine works in enhancing CMV-specific immunity and preventing CMV viremia in patients undergoing haploidentical hematopoietic stem cell transplant. Haploidentical stem cel…

    Stage

    Phase 1

    Ages

    18 to 75

    Site

    City of Hope Medical Center, Duarte, California

    Locations

    3 in total

    Run by

    City of Hope Medical Center

    See if you can join NCT07020533 on ClinicalTrials.gov

23. A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)

    Cancer is a condition where cells in a specific part of the body grow and reproduce uncontrollably. Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow (the spongy tissue inside the bones) that affects white blood cells that helps to fight infections and also prevents normal blood…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    City of Hope National Medical Center /ID# 279568, Duarte, California

    Locations

    38 in total

    Run by

    AbbVie

    See if you can join NCT07581002 on ClinicalTrials.gov

24. Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in AML and MDS

    This is a single institution, prospective study of the whole genome sequencing assay, ChromoSeq. Using prospectively collected patient data, coupled with physician surveys, the investigators seek to determine the feasibility of implementing ChromoSeq in addition to standard genomic testing, for pat…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Washington University School of Medicine, St Louis, Missouri

    Run by

    Washington University School of Medicine

    See if you can join NCT04986657 on ClinicalTrials.gov

25. CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)

    This is a first in human, multi center, open label, phase 1/1b study to evaluate the safety and preliminary efficacy of CER-1236 in patients with relapsed/refractory (R/R), measurable residual disease (MRD) positive acute myeloid leukemia (AML), or TP53mut disease.

    Stage

    Phase 1

    Ages

    18 to 85

    Site

    University of California, Davis Comprehensive Cancer Center, Sacramento, California

    Locations

    5 in total

    Run by

    CERo Therapeutics Holdings, Inc.

    See if you can join NCT06834282 on ClinicalTrials.gov